Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity.
暂无分享，去创建一个
E. Novellino | H. Kessler | F. Rechenmacher | L. Marinelli | F. S. Di Leva | M. Schottelius | S. Neubauer | T. Sobahi | C. Mas-Moruno | R. Brimioulle | A. Bochen | Stefanie Neubauer | Richard Brimioulle